L-去氧肾上腺素 | 614-03-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: L-去氧肾上腺素
• 英文名称: (S)-phenylephrine
• 英文别名: (+)-Phenylephrine；(S)-(+)-Mezaton；phenylephrine；(S)-1-(3-hydroxy-phenyl)-2-methylamino-ethanol；(S)-1-(3-Hydroxy-phenyl)-2-methylamino-aethanol；(S)-3-hydroxy-α[(methylamino)methyl]benzene-methanol；(S)-3-Hydroxy-alpha-((methylamino)methyl)benzyl alcohol；3-[(1S)-1-hydroxy-2-(methylamino)ethyl]phenol
• CAS: 614-03-9
• 化学式: C₉H₁₃NO₂
• 分子量: 167.208
• InChiKey: SONNWYBIRXJNDC-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  52.5
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  L-去氧肾上腺素 在 硫酸 、 乙酸酐 作用下， 生成 [3-[2-[acetyl(methyl)amino]-1-acetyloxyethyl]phenyl] acetate
  参考文献：
  名称：

  �ber Acetylderivate des opt.-akt. Methylaminomethyl-3-oxyphenylcarbinols (Adrianol, m-Synephrin) und die Synthese des (+)-Dimethylaminomethyl-3-oxyphenylcarbinols

  摘要：

  DOI：

  10.1007/bf00899156
• 作为产物：
  描述：

  苯肾上腺素杂质 在 氨 作用下， 以 水 为溶剂， 以94.9%的产率得到L-去氧肾上腺素
  参考文献：
  名称：

  PROCESS FOR RESOLUTION OF 1-(3-HYDROXYPHENYL)-2-METHYLAMINO ETHANOL

  摘要：

  将该化合物分辨到其活性异构体(R)-1-(3-羟基苯基)-2-甲氨基乙醇，使用(R)-萘普生作为分辨剂。

  公开号：

  US20120108848A1

文献信息

• Optically active fluorinated vasoconstrictors, methods for making them, and anesthetic formulations comprising them
  申请人：——

  公开号：US20040002549A1

  公开（公告）日：2004-01-01

  (R)-6F-phenylephrine, essentially free of (S)-6F-phenylephrine, and an anesthetic formulation comprising (R)-6F-epinephrin or (R)-6F-phenylephrine and having improved stability compared to formulations containing their non-fluorinated analog, are disclosed. Further disclosed is a method of providing vasoconstriction in a mammal by administering the anesthetic formulation. The anesthetic composition can include an anesthetic, an (R)-chiral compound having the structure: 1 wherein R 1 , R 2 , and R 4 are independently selected from —H or —F, at least one of R 1 , R 2 , and R 4 is —F, and R 3 is selected from —OH, —H or —F, or a pharmaceutically acceptable salt or ester thereof, said vasoconstrictor being essentially free of the (S)-chiral form. Also, a method of chiral addition of cyanide to a ring-fluorinated phenaldehyde, employing an almond hydroxynitrile lyase enzyme, provided in the form of a reversibly soluble polymer conjugate ((R)-Finezyme™-H series biocatalysts) is disclosed. Several such biocatalysts are disclosed.

  (R)-6F-苯肾上腺素，基本上不含(S)-6F-苯肾上腺素，并且包括(R)-6F-肾上腺素或(R)-6F-苯肾上腺素的麻醉制剂，其相比含有它们非氟化类似物的制剂具有改善的稳定性，已被披露。此外，还披露了通过给予哺乳动物麻醉制剂来提供血管收缩的方法。麻醉组合物可以包括麻醉剂、具有结构的(R)-手性化合物：其中R1、R2和R4独立地选择自—H或—F，R1、R2和R4中至少一个是—F，R3选择自—OH、—H或—F，或其药用可接受的盐或酯，所述血管收缩剂基本上不含(S)-手性形式。此外，还披露了一种利用杏仁羟基亚硝基酰酶酶将氰化物立体加到环氟化苯甲醛的方法，采用可逆溶解聚合物共轭形式提供(R)-Finezyme™-H系列生物催化剂。还披露了几种这样的生物催化剂。
• [EN] INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS<br/>[FR] INHIBITEURS D'ARGINASE ET LEURS APPLICATIONS THÉRAPEUTIQUES
  申请人：MARS INC

  公开号：WO2011133653A1

  公开（公告）日：2011-10-27

  Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity : Formule (I), (II) where R1, R2, R3, R4, R5, R6, R7, R8, R9, D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.

  根据式I和式II，化合物是Arginase I和II活性的强效抑制剂：式(I)，(II)中的R1、R2、R3、R4、R5、R6、R7、R8、R9、D、M、X和Y的定义如规范所述。该发明还提供了这些化合物的药物组合物以及它们用于治疗或预防与Arginase活性相关的疾病或病况的方法。
• [EN] SYNTHESIS OF ENANTIOMERICALLY PURE 2-HYDROXY-2-ARYL-ETHYLAMINES<br/>[FR] SYNTHÈSE DE 2-HYDROXY-2-ARYL-ÉTHYLAMINES ÉNANTIOMÉRIQUEMENT PURES
  申请人：CAMBREX CHARLES CITY INC

  公开号：WO2009086283A1

  公开（公告）日：2009-07-09

  The present invention relates to an improved process for preparing enantiomerically pure 2-hydroxy-2-aryl-ethylamines, and their pharmaceutically acceptable salts, by transition metal catalyzed asymmetric hydrogenation preferably using a ruthenium transition metal catalyst system having as a chiral, bidentate phosphine ligand ((R)-I -diphenylphosphino-2- [(S)-α-(N,N-dimethylamino)-o-diphenylphosphinophenyl)methyl] ferrocene), such as Chiralyst LM 1010 RS available from Umicore AG & Co., KG.

  本发明涉及一种改进的制备对映纯2-羟基-2-芳基乙基胺及其药学可接受盐的方法，通过过渡金属催化不对称氢化，优选使用具有手性双齿膦配体的钌过渡金属催化剂体系（例如Chiralyst LM 1010 RS，由Umicore AG＆Co. KG提供），该配体为((R)-I-二苯基膦酸-2- [（S）-α-（N，N-二甲基氨基）-o-二苯基膦酸苯基甲基]二茂铁）。
• INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS
  申请人：Van Zandt Michael

  公开号：US20120083469A1

  公开（公告）日：2012-04-05

  Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity: where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.

  根据公式I和公式II的化合物是Arginase I和II活性的有效抑制剂：其中R1，R2，R3，R4，R5，R6，R7，R8，R9，D，M，X和Y的定义如规范中所述。该发明还提供了这些化合物的制药组合物和使用它们治疗或预防与Arginase活性相关的疾病或病况的方法。
• 5-Phenyl-2-oxazole derivatives as anti-inflammatory/antiallergic agents
  申请人：AMERICAN HOME PRODUCTS CORPORATION

  公开号：EP0226342A1

  公开（公告）日：1987-06-24

  There are disclosed compounds of formula wherein X is N or CR2; Y is O, S, NR2, CHR2 or C(R2)2 when n = 0 or N or CR2 when n is 1; p is 0 to 3, providing that when p is 0, X is N; R' is R2 is hydrogen or lower alkyl; R3 is hydrogen, lower alkyl, phenyl, thienyl, furyl, pyridyl, C(R4)3 or -(CH2)gCOOR2; R4 is halo; X is 0 or S and q is 0 to 3; and the pharmaceutically acceptable salts thereof, and their use in the treatment of leukotriene-mediated naso-bronchial obstructive airpassageway conditions, such as allergic rhinitis, allergic bronchial asthma and the like, in psoriasis, ulcerative colitis, rheumatoid arthritis as well as in other immediate hypersensitivity reactions.

  公开了如下式子的化合物 其中 X 是 N 或 CR2； 当 n = 0 时，Y 是 O、S、NR2、CHR2 或 C(R2)2；当 n 为 1 时，Y 是 N 或 CR2； p 为 0 至 3，当 p 为 0 时，X 为 N； R' 是 R2 是氢或低级烷基 R3 是氢、低级烷基、苯基、噻吩基、呋喃基、吡啶基、 C(R4)3或-(CH2)gCOOR2； R4 是卤代；X 是 0 或 S，q 是 0 至 3； 及其药学上可接受的盐，以及它们在治疗白三烯介导的鼻-支气管阻塞性气道疾病（如过敏性鼻炎、过敏性支气管哮喘等）、银屑病、溃疡性结肠炎、类风湿性关节炎以及其他即时超敏反应中的用途。

表征谱图